Oral Abstract Schedule

Thursday Oral Abstract Schedule

1:30 - 2:00 pmDr. Neal MauldinSOTA PRESENTATION:
Creation of stereotactic radiosurgery target volumes in patients with
marginally resected tumors using liquid fiducial
Sponsored by Avante Oncology Services
2:00 - 2:15 pmDr. Steven MoiranoEfficacy of frameless stereotactic radiotherapy for the treatment of presumptive
canine intracranial gliomas: A retrospective analysis (2014-2017)
2:15 - 2:30 pmDr. Tiffany Wormhoudt3D-printed bolus improves dose distribution for veterinary patients
treated with photon beam radiation therapy
2:30 - 2:45 pmDr. Valerie PoirerComputed Tomography (CT) vs. Magnetic Resonance Imaging (MRI) for
canine intracranial tumor target contouring in radiotherapy
2:45 - 3:00 pmDr. Audrey StevensOutcome of definitive-intent intensity-modulated radiation therapy for stage 4
canine sinonasal tumors: 29 cases (2011-2017)
3:00 - 3:30 pmResident poster introductions (main ballroom)
3:30 - 5:00 pmPoster viewing, Resident poster judging and afternoon break


Friday Oral Abstract Schedule

8:00 - 9:00 amDr. JP ShenKEYNOTE PRESENTATION:
Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions
Sponsored by VetDC
9:00 - 915 amDr. Jacob CawleyRabacfosadine/Asparaginase for relapsed/refractory canine lymphoma
9:15 - 9:30 amDr. Pierre BoyeA randomized double-blind trial investigating the efficacy and safety of a new
polyamine-vectorized anticancer drug (FYes45YesNO) for treatment of P-glycoprotein
overexpressing non-Hodgkin lymphoma in dogs
9:30 - 9:45 amDr. Monica FernandezWeight change in patients with multicentric lymphoma undergoing 15-week CHOP chemotherapy
9:45 - 10:00 amDr. Chia-Lien KaoComparison of efficacy and adverse event of 15-week CHOP protocol
with 25-week protocol in canine multicentric lymphoma
of NTUVH: 2010-2018
10:00 - 10:30amMorning Break
10:30 - 11:00 amDr. Travis LaverSOTA PRESENTATION:
NF-kappa B activation status and proteasome inhibition in canine osteosarcoma
Sponsored by Equashield
11:00 - 11:15 amDr. Michelle LaRueCD4+CD25+ T cell Foxp3 expression is not increased in cats
with cancer when compared to healthy controls
11:15 - 11:30 amDr. Margaret MusserExpression of prostaglandin EP4 receptor in multiple canine malignancies
11:30 - 11:45 amDr. Shawna KlahnThe impact of neoadjuvant prednisone on grade and proliferation indices
in canine cutaneous mast cell tumors: A pilot study
11:45 am - 12:00 pmDr. Lucas RodriguesPhase I clinical study to determine the maximal tolerated dose and
dose-limiting toxicities of orally dichloroacetate in dogs with spontaneous tumors
1:30 - 2:30 pmDr. Andrew GodwinKEYNOTE PRESENTATION:
Liquid gold in precision medicine:
Liquid-based biopsies for cancer detection and monitoring
Sponsored by Puppy Up
2:30 - 2:45 pmDr. Anthony RuskA clinical trial to evaluate the safety and preliminary efficacy
of surgery and ECI-VAR-1in the treatment of dogs with osteosarcoma
2:45 - 3:00 pmDr. Lynn GriffinThe prognostic significance of F18 – FDG PET/CT in dogs
with appendicular osteosarcoma
3:00 - 3:15 pmDr. Stewart LowdenDose characterization of the investigational anticancer agent
tigilanol tiglate (EBC-46) in the local treatment of canine cutaneous
mast cell tumors (MCT)
3:15 - 3:45 pmAfternoon Break
3:45 - 4:15 pmDr. Jeffrey BryanSOTA PRESENTATION:
F-18-FDG PET scan predicts regions of highest mitotic activity in
high grade soft-tissue sarcomas and liposarcomas
Sponsored by Elias Animal Health
4:15 - 4:30 pmDr. Xuan PanTargeting NF-kappa B pathway in canine diffuse large B cell lymphoma
4:30 - 4:45 pmDr. Benjamin LeeEvaluation of NFκB signaling in feline injection site sarcomas in vitro
and ex vivo as a potential novel therapeutic target of Bortezomib
4:45 - 5:00 pmDr. Ludmila BicanovaAlternative lengthening of telomeres (ALT): A potential prognostic
marker in canine appendicular osteosarcoma


Saturday Oral Abstract Schedule

8:00 - 9:00 AMDr. Katherine GoldbergKEYNOTE PRESENTATION:
Moving upstream: Transformative oncology practice through
a palliative care lens
Sponsored by Vivos, Inc.

9:00 - 9:15 AMDr. Alycen LundbergTargeted therapy for feline oral squamous cell carcinoma through exploitation
of NQO1 protein with radiation therapy and the drug isobutyl-deoxynyboquinone
(IB-DNQ): Results of a prospective clinical trial evaluating 18 cats
9:15 - 9:30 amDr. Michael KorenkoDirected high-dose radionuclide therapy of soft-tissue sarcoma
9:30 - 9:45 amDr. Alexandra
P-selectin expression in canine tumors, a potential target for
nanomolecular chemotherapy delivery
9:45 - 10:00 amDr. Breann SommerBasal and luminal molecular subtypes in canine invasive
urothelial carcinoma
10:00 - 10:30 amMorning Break
10:30 - 11:00 amDr. Erin BanninkSOTA PRESENTATION:
The potential role of traditional Chinese herbal medicine in treating
canine splenic hemangiosarcoma
Sponsored by Hope Veterinary Specialists
11:00 - 11:15 amDr. Pascale SalahEvaluation of the safety of a recombinant adenoviral vector encoding an
anti-VEGF antibody and its ability to delay tumor progression and prolong
survival in dogs with splenic hemangiosarcoma
11:15 - 11:30 amDr. Minami GotoTumor necrosis factor-related apoptosis inducing ligand (TRAIL) induces apoptosis to canine
hemangiosarcoma cells in vitro
11:30 - 11:45 amDr. Lisa ParshleySafety and efficacy of nanoparticle thermal ablation of solid tumors
11:45 - 12:00 pmDr. Robin HollandEvaluating the rationale and feasibility of IB-DNQ intravesicular infusion therapy
for transitional cell carcinoma
1:30 - 1:45 pmDr. Ann HonhenhausProof of concept study of AFPep as a new treatment for canine
mammary gland cancer
1:45 - 2:00 pmDr. Darren BergerEvaluation of the potency and accuracy of compounded toceranib
phosphate formulations
2:00 - 2:15 pmDr. Eric FishEvaluation of region of interest (ROI) digital cytology compared to light
microscopy for veterinary medicine: A concordance study (60 cases)
2:15 - 2:30 pmMs. Katherine R. LuethckeImpact of glutathione S-transferase theta genotype and household environmental
exposures on risk for transitional cell carcinoma in the dog
2:30 - 2:45 pmDr. Brian FlesnerAutologous activated T cell therapy for canine osteosarcoma
2:45 - 3:00 pmDr. Ashish RanjanFeasibility of solid tumor and non-healing would treatment
in veterinary patients with focused ultrasound technology
1:30 - 1:45 pmDr. Dana ConnellUpregulation of the hedgehog pathway and associated anti-apoptotic factors can be
inhibited by itraconazole in canine osteosarcoma cell lines
1:45 - 2:00 pmDr. Tim FanRational combination of doxorubicin and PAC-1 for sensitization and treatment of
measurable canine pulmonary osteosarcoma metastases
2:00 - 2:15 pmMr. Andrew PoonThe sodium-hydrogen exchanger NHE1 is linked to chemoresistance and invasion in canine osteosarcoma cells
2:15 - 2:30 pmDr. Masaya IgaseDEP domain containing 1B (DEPDC1B) expression in canine lymphoma
2:30 - 2:45 pmDr. Nikolaos DervisisTargeting Akt signaling pathway in canine histiocytic sarcoma
2:45 - 3:00 pmDr. Osamu SakaiGeneration of canine CD20 chimeric antigen receptor T cells and in vitro
evaluation of cytotoxic effect on canine B cell lymphoma
3:00 - 3:30 pmAfternoon Break